Report Detail
Global (United States, European Union and China) Immune Checkpoint Inhibitors Market Research Report 2019-2025
- RnM3713263 |
- 30 August, 2019 |
- Global |
- 128 Pages |
- QYResearch |
- Pharma & Healthcare
Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.
In 2019, the market size of Immune Checkpoint Inhibitors is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Immune Checkpoint Inhibitors.
This report studies the global market size of Immune Checkpoint Inhibitors, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Immune Checkpoint Inhibitors sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Bristol Myer Squibb
AstraZeneca
Merck & Co.
Roche / Genentech
Incyte Corporation
NewLink Genetics
ArGEN-X
Seattle Genetics
Pfizer
MacroGenics
Celldex Therapeutics
CureTech
Immutep
Innate Pharma
Sorrento Therapeutics
GlaxoSmithKline
GITR, Inc
Market Segment by Product Type
PD-1/PD-L1
CTLA-4
Market Segment by Application
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Other
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Immune Checkpoint Inhibitors status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Immune Checkpoint Inhibitors manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Immune Checkpoint Inhibitors are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Immune Checkpoint Inhibitors Market Size Growth Rate by Type (2019-2025)
- 1.3.2 PD-1/PD-L1
- 1.3.3 CTLA-4
- 1.4 Market Segment by Application
- 1.4.1 Global Immune Checkpoint Inhibitors Market Share by Application (2019-2025)
- 1.4.2 Lung Cancer
- 1.4.3 Colorectal Cancer
- 1.4.4 Breast Cancer
- 1.4.5 Prostate Cancer
- 1.4.6 Melanoma
- 1.4.7 Blood Cancer
- 1.4.8 Other
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Immune Checkpoint Inhibitors Market Size
- 2.1.1 Global Immune Checkpoint Inhibitors Revenue 2014-2025
- 2.1.2 Global Immune Checkpoint Inhibitors Sales 2014-2025
- 2.2 Immune Checkpoint Inhibitors Growth Rate by Regions
- 2.2.1 Global Immune Checkpoint Inhibitors Sales by Regions 2014-2019
- 2.2.2 Global Immune Checkpoint Inhibitors Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Immune Checkpoint Inhibitors Sales by Manufacturers
- 3.1.1 Immune Checkpoint Inhibitors Sales by Manufacturers 2014-2019
- 3.1.2 Immune Checkpoint Inhibitors Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Immune Checkpoint Inhibitors Revenue by Manufacturers (2014-2019)
- 3.2.2 Immune Checkpoint Inhibitors Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Immune Checkpoint Inhibitors Market Concentration Ratio (CR5 and HHI)
- 3.3 Immune Checkpoint Inhibitors Price by Manufacturers
- 3.4 Key Manufacturers Immune Checkpoint Inhibitors Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Immune Checkpoint Inhibitors Market
- 3.6 Key Manufacturers Immune Checkpoint Inhibitors Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 PD-1/PD-L1 Sales and Revenue (2014-2019)
- 4.1.2 CTLA-4 Sales and Revenue (2014-2019)
- 4.2 Global Immune Checkpoint Inhibitors Sales Market Share by Type
- 4.3 Global Immune Checkpoint Inhibitors Revenue Market Share by Type
- 4.4 Immune Checkpoint Inhibitors Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Immune Checkpoint Inhibitors Sales by Application
6 United States
- 6.1 United States Immune Checkpoint Inhibitors Breakdown Data by Company
- 6.2 United States Immune Checkpoint Inhibitors Breakdown Data by Type
- 6.3 United States Immune Checkpoint Inhibitors Breakdown Data by Application
7 European Union
- 7.1 European Union Immune Checkpoint Inhibitors Breakdown Data by Company
- 7.2 European Union Immune Checkpoint Inhibitors Breakdown Data by Type
- 7.3 European Union Immune Checkpoint Inhibitors Breakdown Data by Application
8 China
- 8.1 China Immune Checkpoint Inhibitors Breakdown Data by Company
- 8.2 China Immune Checkpoint Inhibitors Breakdown Data by Type
- 8.3 China Immune Checkpoint Inhibitors Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Immune Checkpoint Inhibitors Breakdown Data by Company
- 9.2 Rest of World Immune Checkpoint Inhibitors Breakdown Data by Type
- 9.3 Rest of World Immune Checkpoint Inhibitors Breakdown Data by Application
- 9.4 Rest of World Immune Checkpoint Inhibitors Breakdown Data by Countries
- 9.4.1 Rest of World Immune Checkpoint Inhibitors Sales by Countries
- 9.4.2 Rest of World Immune Checkpoint Inhibitors Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Bristol Myer Squibb
- 10.1.1 Bristol Myer Squibb Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
- 10.1.4 Immune Checkpoint Inhibitors Product Introduction
- 10.1.5 Bristol Myer Squibb Recent Development
- 10.2 AstraZeneca
- 10.2.1 AstraZeneca Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
- 10.2.4 Immune Checkpoint Inhibitors Product Introduction
- 10.2.5 AstraZeneca Recent Development
- 10.3 Merck & Co.
- 10.3.1 Merck & Co. Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
- 10.3.4 Immune Checkpoint Inhibitors Product Introduction
- 10.3.5 Merck & Co. Recent Development
- 10.4 Roche / Genentech
- 10.4.1 Roche / Genentech Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
- 10.4.4 Immune Checkpoint Inhibitors Product Introduction
- 10.4.5 Roche / Genentech Recent Development
- 10.5 Incyte Corporation
- 10.5.1 Incyte Corporation Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
- 10.5.4 Immune Checkpoint Inhibitors Product Introduction
- 10.5.5 Incyte Corporation Recent Development
- 10.6 NewLink Genetics
- 10.6.1 NewLink Genetics Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
- 10.6.4 Immune Checkpoint Inhibitors Product Introduction
- 10.6.5 NewLink Genetics Recent Development
- 10.7 ArGEN-X
- 10.7.1 ArGEN-X Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
- 10.7.4 Immune Checkpoint Inhibitors Product Introduction
- 10.7.5 ArGEN-X Recent Development
- 10.8 Seattle Genetics
- 10.8.1 Seattle Genetics Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
- 10.8.4 Immune Checkpoint Inhibitors Product Introduction
- 10.8.5 Seattle Genetics Recent Development
- 10.9 Pfizer
- 10.9.1 Pfizer Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
- 10.9.4 Immune Checkpoint Inhibitors Product Introduction
- 10.9.5 Pfizer Recent Development
- 10.10 MacroGenics
- 10.10.1 MacroGenics Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Immune Checkpoint Inhibitors
- 10.10.4 Immune Checkpoint Inhibitors Product Introduction
- 10.10.5 MacroGenics Recent Development
- 10.11 Celldex Therapeutics
- 10.12 CureTech
- 10.13 Immutep
- 10.14 Innate Pharma
- 10.15 Sorrento Therapeutics
- 10.16 GlaxoSmithKline
- 10.17 GITR, Inc
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Immune Checkpoint Inhibitors Sales Channels
- 11.2.2 Immune Checkpoint Inhibitors Distributors
- 11.3 Immune Checkpoint Inhibitors Customers
12 Market Forecast
- 12.1 Global Immune Checkpoint Inhibitors Sales and Revenue Forecast 2019-2025
- 12.2 Global Immune Checkpoint Inhibitors Sales Forecast by Type
- 12.3 Global Immune Checkpoint Inhibitors Sales Forecast by Application
- 12.4 Immune Checkpoint Inhibitors Forecast by Regions
- 12.4.1 Global Immune Checkpoint Inhibitors Sales Forecast by Regions 2019-2025
- 12.4.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Immune Checkpoint Inhibitors. Industry analysis & Market Report on Immune Checkpoint Inhibitors is a syndicated market report, published as Global (United States, European Union and China) Immune Checkpoint Inhibitors Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Immune Checkpoint Inhibitors market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
